DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
ELAN logo

Elanco Animal Health Incorporated Stock Price

NYSE:ELAN Community·US$11.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ELAN Share Price Performance

US$22.86
4.43 (24.04%)
​
US$31.21
Fair Value
US$22.86
4.43 (24.04%)
26.8% undervalued intrinsic discount
US$31.21
Fair Value
Price US$22.86
AnalystConsensusTarget US$31.21
AnalystLowTarget US$26.82
AnalystHighTarget US$34.00
Thu, 20 Aug 26
Fair ValueUS$31.21
Share Pricen/a

ELAN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$31.21 26.8% undervalued intrinsic discount

Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$26.82 14.8% undervalued intrinsic discount

Mounting Debt And Patent Risks Will Crush Future Net Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$34 32.8% undervalued intrinsic discount

Global Animal Protein Demand Will Drive Breakthroughs Amid Regulatory Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ELAN logo
Elanco Animal Health
26.8% undervalued intrinsic discount

Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Aug
Read Narrative
ELAN logo
Elanco Animal Health
14.8% undervalued intrinsic discount

Mounting Debt And Patent Risks Will Crush Future Net Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 23 Jul
Read Narrative
ELAN logo
Elanco Animal Health
32.8% undervalued intrinsic discount

Global Animal Protein Demand Will Drive Breakthroughs Amid Regulatory Risks

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
ELAN logo

ELAN: Blockbuster Pipeline And Margin Gains Will Shape 2026 Upside Potential

Fair Value: US$31.21 26.8% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
ELAN logo

ELAN: Future Blockbuster Launches Will Drive Upside As Guidance Strengthens

Fair Value: US$34 32.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
ELAN logo

ELAN: Blockbuster Launches And Sluggish Vet Visits Will Shape Fairly Valued Outlook

Fair Value: US$26.82 14.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

0 Risks
4 Rewards
View Full Analysis

Elanco Animal Health Incorporated Key Details

US$5.0b

Revenue

US$2.2b

Cost of Revenue

US$2.8b

Gross Profit

US$3.0b

Other Expenses

-US$199.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 06, 2026
-0.40
55.36%
-3.96%
60.4%
View Full Analysis

About ELAN

Founded
1954
Employees
9650
CEO
Jeffrey Simmons
WebsiteView website
www.elanco.com

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Recent ELAN News & Updates

Recent updates

No updates

Elanco Animal Health Incorporated Competitors

REGN logo

Regeneron Pharmaceuticals

Symbol: NasdaqGS:REGN
Market cap: US$77.3b
MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$58.1b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$50.6b
TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$45.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide